ASTEX PHARMACEUTICALS, INC COM
ASTX
ASTX was delisted on the 10th of October, 2013.
123 hedge funds and large institutions have $487M invested in ASTEX PHARMACEUTICALS, INC COM in 2013 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 38 closing their positions.
128% more capital invested
Capital invested by funds: $214M → $487M (+$273M)
11% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 38
3% more funds holding
Funds holding: 120 → 123 (+3)
7% more call options, than puts
Call options by funds: $31.7M | Put options by funds: $29.7M
3% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAL
TIG Advisors LLC
New York
|
+$23M |
| 2 |
CM
Corvex Management
New York
|
+$15.5M |
| 3 |
WIC
Water Island Capital
New York
|
+$14.5M |
| 4 |
SAM
Sandell Asset Management
New York
|
+$13.3M |
| 5 |
Millennium Management
New York
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.4M |
| 2 |
O
OrbiMed
New York
|
-$13.4M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.4M |
| 4 |
PA
Perceptive Advisors
New York
|
-$10.1M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$7.56M |
ASTX Hedge Fund Activity: Q3 2013 in Review
123 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in ASTEX PHARMACEUTICALS, INC COM (ASTX) for Q3 2013, worth a combined $487M — up 128% from $214M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ASTX positions and 38 closed out — a net gain of 4 holders — while 31 added to existing stakes and 32 trimmed.
The largest buyer was TIG Advisors LLC, opening a new position worth an estimated $23M. The largest seller was Fidelity Investments, cutting an estimated $21.4M.
- 123 institutional investors held ASTEX PHARMACEUTICALS, INC COM (ASTX) as of Q3 2013, up from 120 in Q2 2013.
- Funds reported $487M of ASTEX PHARMACEUTICALS, INC COM stock for Q3 2013, up 128% quarter-over-quarter.
- 42 funds opened new ASTEX PHARMACEUTICALS, INC COM positions in Q3 2013 and 38 closed out, a net change of +4 holders.
- The largest ASTEX PHARMACEUTICALS, INC COM buyer in Q3 2013 was TIG Advisors LLC, an estimated $23M added.
- The largest ASTEX PHARMACEUTICALS, INC COM seller in Q3 2013 was Fidelity Investments, an estimated $21.4M sold.
Based on aggregated 13F filings for Q3 2013.